List of Excipients in Branded Drug ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

Generic Drugs Containing ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	atovaquone and proguanil hydrochloride	0378-4160	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	atovaquone and proguanil hydrochloride	0378-4160	CROSPOVIDONE
Mylan Pharmaceuticals Inc	atovaquone and proguanil hydrochloride	0378-4160	FERRIC OXIDE RED

What are the Most Frequently-Used Excipients in ATOVAQUONE AND PROGUANIL HYDROCHLORIDE?

# Of NDCs	Excipient
16	CELLULOSE, MICROCRYSTALLINE
2	CROSPOVIDONE
16	FERRIC OXIDE RED

Last updated: September 23, 2026

The main commercial opportunity for atovaquone and proguanil hydrochloride is an improved oral product that increases atovaquone exposure, reduces food dependence, and improves pediatric acceptability. The reference product, Malarone, uses a conventional tablet excipient system, while atovaquone’s poor aqueous solubility creates room for lipid-based, amorphous, nanosized, and suspension technologies. In the United States, the core combination is a mature generic market with limited current regulatory exclusivity. New intellectual-property value is more likely to come from differentiated formulations, pediatric delivery, manufacturing processes, or region-specific regulatory packages than from the active ingredients.

Atovaquone and Proguanil Hydrochloride Excipient Strategy and Commercial Opportunities

What is the formulation challenge for atovaquone and proguanil hydrochloride?

Atovaquone is the formulation-limiting component. It is highly lipophilic, practically insoluble in water, and has variable oral absorption. Food, particularly a meal containing dietary fat, materially increases atovaquone exposure. Proguanil hydrochloride is more water soluble and does not create the same absorption constraint.[1]

The fixed-dose combination therefore presents an asymmetric formulation problem:

Attribute	Atovaquone	Proguanil hydrochloride
Dose in adult tablet	250 mg	100 mg
Primary formulation issue	Poor aqueous solubility and variable absorption	Bitterness, dose uniformity, stability
Food effect	Clinically important	Less limiting
Key excipient objective	Wetting, dispersion, dissolution, absorption	Taste masking, flow, compressibility
Main commercial risk	Subtherapeutic exposure if administered without food	Poor adherence, especially in children

The current reference product addresses the problem through a conventional immediate-release tablet and labeling that instructs administration with food or a milky drink. That instruction creates a commercial opening for formulations that reduce dependence on meal composition.

What excipients are used in Malarone tablets?

Malarone adult and pediatric tablets use a conventional excipient platform. The U.S. prescribing information identifies the following inactive ingredients for the tablets:

Excipient or coating component	Likely formulation function
Poloxamer 188	Wetting and dispersion of atovaquone
Low-substituted hydroxypropyl cellulose	Disintegrant and matrix-forming aid
Povidone K30	Binder and granulation aid
Sodium starch glycolate	Tablet disintegration
Magnesium stearate	Lubricant
Hypromellose	Film coating
Titanium dioxide	Opacifier and color control
Polyethylene glycol 400	Coating plasticizer
Red ferric oxide	Tablet colorant

The listed composition applies to the labeled Malarone tablet presentation, subject to jurisdictional and product-version differences.[1] Generic manufacturers may use different excipient systems if the finished product meets relevant pharmaceutical equivalence, bioequivalence, quality, and safety requirements.

The reference formulation is commercially useful as a benchmark, but it is not the only viable platform. A generic developer can select different excipients if it controls dissolution, content uniformity, impurity formation, mechanical properties, and in vivo exposure.

Which excipients can improve atovaquone dissolution and bioavailability?

The strongest formulation opportunities target wetting, particle size, solid-state behavior, and drug dispersion.

Surfactant and wetting systems

Poloxamer 188 is already used in the reference tablet. Other development options can include:

• Polysorbates, subject to oxidation and peroxide control.
• Sodium lauryl sulfate, subject to tolerability and dissolution optimization.
• Docusate or other wetting agents where permitted by the target jurisdiction.
• Nonionic surfactant blends for liquid or lipid-based systems.

Surfactant concentration must remain below levels that create gastrointestinal intolerance, excessive foaming, instability, or dissolution artifacts. The objective is not maximum solubilization in vitro. It is reproducible exposure at the intended dose.

Particle-size reduction

Micronized or nanocrystalline atovaquone can increase surface area and improve dissolution. The principal controls are:

• Particle-size distribution.
• Agglomeration during storage.
• Electrostatic charging during blending.
• Content uniformity at the relatively high atovaquone load.
• Milling-related amorphization or impurity generation.

Nanocrystal technology can support tablets, oral suspensions, or orally dispersible products. It also creates manufacturing know-how that may support process patents, although patent strength depends on clearly defined particle-size, stabilizer, process, and performance claims.

Amorphous solid dispersions

An amorphous dispersion can improve apparent solubility by embedding atovaquone in a polymeric carrier. Candidate polymer classes include hypromellose acetate succinate, hypromellose, polyvinylpyrrolidone, copovidone, and related precipitation-inhibiting polymers.

The main risks are recrystallization, moisture sensitivity, thermal stress, and scale-up. A robust product needs solid-state characterization using techniques such as powder X-ray diffraction, differential scanning calorimetry, microscopy, and accelerated stability testing.

Lipid-based delivery

Lipidic excipients are commercially attractive because atovaquone’s lipophilicity may allow improved dissolution in a fed-state-like environment. Candidate systems include:

• Medium-chain triglycerides.
• Long-chain triglycerides.
• Mixed glycerides.
• Self-emulsifying drug-delivery systems.
• Surfactant and co-surfactant mixtures.
• Softgel or liquid-filled capsule systems.

The commercial advantage is the potential to reduce the food effect. The disadvantages include capsule manufacturing complexity, oxidation control, fill-volume constraints, packaging requirements, and a more demanding regulatory comparability argument.

What formulation platforms offer the best commercial opportunity?

Platform	Bioavailability potential	Pediatric suitability	Manufacturing complexity	IP potential	Commercial view
Conventional immediate-release tablet	Moderate	Moderate	Low	Low	Best route for cost-driven generic entry
Micronized tablet	Moderate to high	Moderate	Moderate	Moderate	Practical improvement if dissolution is reliable
Nanocrystal tablet or suspension	High	High	High	High	Strong differentiated-product opportunity
Amorphous solid dispersion	High	Moderate	High	High	Attractive but stability-sensitive
Lipid-based capsule	High	Low to moderate	High	High	More suitable for adult travel market
Ready-to-use suspension	Moderate to high	High	Moderate	Moderate	Strong pediatric and institutional opportunity
Powder for reconstitution	Moderate to high	High	Moderate	Moderate	Lower shipping weight and improved shelf-life potential
Orally dispersible tablet	Moderate	High	Moderate	Moderate	Useful where swallowing and water access are limiting

A conventional tablet remains the lowest-risk generic strategy. A suspension, dispersible tablet, or nanocrystal product offers greater pricing and market differentiation but carries higher development and regulatory risk.

What excipient strategy is best for pediatric atovaquone and proguanil?

Pediatric products need dose flexibility, taste masking, physical stability, and easy administration. The labeled pediatric strength contains 62.5 mg of atovaquone and 25 mg of proguanil hydrochloride per tablet.[1]

A commercially competitive pediatric platform should address:

1. Bitterness from proguanil and the overall chalky or insoluble mouthfeel associated with atovaquone.
2. Dose adjustment without tablet splitting.
3. Sedimentation and redispersibility in liquid products.
4. Palatability after repeated daily dosing.
5. Preservative and microbial-control requirements.
6. Compatibility with common administration vehicles.
7. Low sugar or sugar-free positioning where clinically useful.

Potential liquid-product excipient categories include suspending agents such as xanthan gum or cellulose derivatives, wetting agents, sweeteners, flavors, buffering agents, and preservatives. The final composition must be selected through palatability, stability, preservative-effectiveness, and drug-release testing rather than by excipient availability alone.

A powder for reconstitution may offer a better stability profile than a ready-to-use suspension. It can also reduce transportation weight. Its weakness is the need for accurate reconstitution and clear caregiver instructions.

Taste masking can use polymer coating, ion pairing, lipid coating, microspheres, or multiparticulate delivery. A coating that delays release in the mouth but rapidly releases the drug in the gastrointestinal tract is preferable to a heavy coating that creates a dissolution failure.

When does atovaquone and proguanil lose exclusivity?

The active ingredients and the core fixed-dose combination are mature products. Malarone was approved in the United States in the late 1990s, and pediatric labeling followed later.[2] The core compound and basic combination exclusivity periods have expired.

Exclusivity category	Current commercial relevance
New chemical entity exclusivity	Expired
Original fixed-dose combination protection	Expired
Pediatric exclusivity tied to the original product	Expired
Core active-ingredient patents	Expired or commercially exhausted in major markets
New formulation patents	Potentially available for genuinely differentiated products
Manufacturing-process patents	Potentially available where process claims are novel and enforceable

A current Orange Book review is required for product-specific listed patent and exclusivity status because listings and marketing-status records can change. The strategic conclusion is stable: a company entering with a conventional tablet generally competes on cost, supply, and regulatory execution, not on residual core-product exclusivity.[3]

What is the Orange Book and Paragraph IV status of atovaquone and proguanil?

The FDA Orange Book records approved products, therapeutic-equivalence evaluations, patents, and exclusivity information for relevant drug products.[3] Atovaquone and proguanil hydrochloride generic entry is primarily an ANDA opportunity when the proposed product matches the reference product in dosage form, strength, route, and relevant performance characteristics.

Paragraph IV risk depends on whether an applicable patent is listed against the reference product. For a mature product with no meaningful active listed patent blocking the conventional formulation, Paragraph IV litigation is less central than ordinary ANDA review and commercial launch timing.

A developer of a materially different product may instead consider:

• An ANDA, if the product can establish sameness and bioequivalence.
• A 505(b)(2) application, if the formulation, dosage form, route, or clinical bridge requires reliance on existing findings but is not suitable for an ANDA.
• A full new drug application, if the product introduces a sufficiently different clinical or pharmacologic profile.

A novel suspension, long-acting system, or formulation designed to remove the food effect may not fit cleanly within a conventional ANDA strategy.

Which companies are challenging or competing with Malarone?

Competition comes from generic manufacturers rather than biosimilar developers. Atovaquone and proguanil hydrochloride is a small-molecule combination, so the relevant competitors are ANDA holders, regional suppliers, contract manufacturers, and malaria-focused public-sector vendors.

The competitive landscape has four segments:

Segment	Competitive basis
U.S. generic tablets	Price, supply reliability, therapeutic equivalence
European and UK generics	National authorization, tender access, distributor reach
African and Asian public-sector supply	Cost, procurement qualification, quality documentation
Differentiated formulations	Pediatric acceptability, food-effect reduction, dosing convenience

Biosimilar risk is not applicable. No biologic reference product or biosimilar pathway is involved.

What patent opportunities exist for excipients and formulations?

The strongest patent opportunities are formulation-specific rather than ingredient-specific.

Formulation patents

Potential claim areas include:

• Defined atovaquone particle-size distributions.
• Nanocrystal compositions with specified stabilizer ratios.
• Self-emulsifying systems with defined lipid and surfactant ranges.
• Amorphous dispersions with specified polymer-to-drug ratios.
• Taste-masked multiparticulates.
• Ready-to-use suspensions with defined sedimentation and redispersion performance.
• Orally dispersible dosage forms with rapid disintegration and controlled dissolution.
• Combination products with reduced food-effect dependence.

Broad claims covering any excipient that improves dissolution are vulnerable to prior-art and enablement challenges. Stronger claims define composition, process, measurable performance, and stability together.

Manufacturing-process patents

Process protection may cover:

• High-energy wet milling.
• Controlled precipitation of atovaquone nanocrystals.
• Spray drying of a polymeric dispersion.
• Solvent-removal conditions.
• Granulation sequence and excipient addition order.
• Moisture-controlled coating or encapsulation.

Manufacturing patents can be valuable where the process produces a measurable product attribute that competitors cannot easily avoid.

Method-of-use patents

Method-of-use claims for malaria prophylaxis and treatment are difficult to differentiate because the core uses are established. More defensible opportunities may involve:

• Administration without a high-fat meal.
• Use in a defined pediatric population with a particular dosage form.
• Use with a specific delivery system that changes pharmacokinetic performance.

Such claims face validity and infringement challenges if the clinical benefit is not clearly demonstrated.

What regulatory barriers affect an improved excipient formulation?

The main regulatory barrier is proving that formulation improvements do not create unacceptable exposure differences.

Critical studies may include:

• Comparative dissolution across multiple pH conditions.
• Fed and fasted pharmacokinetics.
• Food-effect studies.
• Dose proportionality.
• Particle-size and solid-state characterization.
• Bioequivalence against the appropriate reference product.
• Pediatric palatability and administration studies.
• Suspension redispersibility and in-use stability.
• Extractables and leachables for liquid or lipid systems.
• Preservative effectiveness for multidose products.

Atovaquone exposure is especially important because insufficient absorption can reduce clinical protection. A formulation that produces higher exposure may also create safety questions, even if the active ingredients have established clinical use.

What generic launch scenarios exist?

Low-cost tablet launch

This is the fastest and least differentiated route. It relies on conventional excipients, demonstrated bioequivalence, and efficient supply. The likely market position is price competition.

Pediatric suspension or dispersible product

This route can capture travel medicine, pediatric prescribing, private pharmacies, humanitarian procurement, and markets where swallowing tablets is difficult. Commercial value depends heavily on taste, shelf life, and dose flexibility.

Food-effect-reducing product

A product that maintains exposure with limited dietary fat could support premium positioning. It needs convincing pharmacokinetic evidence and clear labeling advantages.

High-barrier nanocrystal or lipid product

This route can generate formulation IP and reduce direct substitutability with standard tablets. It requires higher capital, stronger process controls, and a broader regulatory package.

How does atovaquone and proguanil compare with other antimalarial products?

Product	Main formulation advantage	Main limitation
Atovaquone/proguanil	Short prophylaxis course and convenient fixed-dose combination	Atovaquone food effect and cost
Doxycycline	Low-cost generic and broad availability	Daily dosing, photosensitivity, contraindications
Mefloquine	Weekly prophylaxis	Neuropsychiatric and tolerability concerns
Tafenoquine	Single-dose or weekly-use potential in specific settings	G6PD testing and regulatory restrictions
Chloroquine	Low cost for susceptible parasites	Resistance limits use
Artemisinin-based combinations	Strong treatment role in malaria-endemic regions	Different regulatory and resistance considerations

Atovaquone/proguanil is most commercially differentiated in travel medicine and short-course prophylaxis. Its formulation value is highest where adherence, pediatric use, and food-independent administration affect product choice.

What revenue exposure and licensing opportunities exist?

The commercial opportunity is concentrated in three areas:

1. Replacement of conventional tablet volume through lower-cost generic supply.
2. Premium pediatric and patient-friendly products.
3. Licensing of enabling technologies for solubility enhancement, taste masking, or suspension manufacture.

A company with an excipient platform, nanocrystal process, or lipid formulation can license technology to generic manufacturers without owning the full global marketing operation. Potential counterparties include established generic companies, travel-health suppliers, contract development and manufacturing organizations, and public-sector procurement specialists.

Revenue should not be modeled from Malarone brand sales alone. The market is fragmented by geography, generic substitution, travel volumes, malaria epidemiology, public procurement, and pricing pressure. The strongest investment case is a differentiated formulation with demonstrable pharmacokinetic or adherence advantages, not an undifferentiated tablet.

Key Takeaways

• Atovaquone is the principal formulation problem because of poor aqueous solubility and food-sensitive absorption.
• The reference tablet uses poloxamer 188, povidone, low-substituted hydroxypropyl cellulose, sodium starch glycolate, magnesium stearate, and a conventional film coat.[1]
• Conventional tablets offer the lowest-cost generic entry but limited patent and pricing differentiation.
• Pediatric suspensions, dispersible tablets, nanocrystals, amorphous dispersions, and lipid systems provide stronger commercial opportunities.
• The most valuable formulation claims will link excipient composition to particle size, dissolution, bioavailability, taste, stability, or food-effect performance.
• No biosimilar pathway applies because the product is a small-molecule combination.
• Core Malarone exclusivity is expired; current Orange Book listings must be checked for product-specific patent status before filing or launch.[3]
• A differentiated product may require a 505(b)(2) strategy rather than a conventional ANDA.
• Licensing value is highest for technologies that reduce food dependence, improve pediatric acceptability, or simplify manufacturing.

FAQs

Can atovaquone and proguanil hydrochloride be formulated as a liquid suspension?

Yes. A liquid suspension is technically feasible, but it requires control of wetting, sedimentation, redispersibility, taste, preservative effectiveness, and in-use stability.

Which excipient is most important for atovaquone dissolution?

No single excipient determines performance. Poloxamer 188 provides wetting in the reference tablet, while particle-size reduction, surfactants, polymers, and lipid systems can provide additional dissolution improvement.

Is a high-fat meal required with every atovaquone and proguanil product?

Food requirements depend on the formulation and clinical labeling. The reference product is administered with food or a milky drink because food increases atovaquone absorption.[1]

Can a new pediatric formulation receive independent patent protection?

Yes, if the formulation is novel, non-obvious, enabled, and supported by adequate disclosure. Potential claim subjects include taste masking, particle engineering, suspension composition, dosing flexibility, and stability.

Is atovaquone and proguanil suitable for a biosimilar development program?

No. It is a small-molecule combination. The relevant pathways are generic drug approval, hybrid approval in some jurisdictions, or a 505(b)(2) application for a materially differentiated formulation.

References

1. U.S. Food and Drug Administration. (n.d.). Malarone: Atovaquone and proguanil hydrochloride tablets, prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Malarone application and approval history.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
4. Centers for Disease Control and Prevention. (2024). CDC Yellow Book: Malaria.
5. World Health Organization. (2023). World malaria report 2023. World Health Organization.